News
J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback